Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

63.96 +0.74 (+1.17%)
Streaming Delayed Price Updated: 11:19 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 Next >
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Third Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
From Exact Sciences Corp.
Via Business Wire
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Second Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Second Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
From Exact Sciences Corp.
Via Business Wire
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules First Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in March Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
From Exact Sciences Corp.
Via Business Wire
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.